Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma

NCT02909777 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

26

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma
Neuroblastoma
Brain Tumor
Solid Tumor

Interventions

DRUG: CUDC-907

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]